ICGC-ARGO CRC
Leading Institution
- The Sixth Affiliated Hospital of Sun Yat-sen University, China
- BGI-Shenzhen, China
- Chinese Cancer Genome Consortium (CCGC)
Program Description
The value of molecular subtype for colorectal cancer in the aspect of disease diagnosis as well as prognostic prediction is still controversial. Therefore, we will assess the combination of multiple-omics, and developed a new individualized signature. Then further validation based on our massively parallel sequencing in 2,000 CRC samples will be carried out in order to evaluate its clinical utility. This constructed signature may uncover the specific molecular sub-type of CRC based on the population of China. Moreover, it will be used in the disease diagnosis and prognostic prediction for CRC patients, especially in the aspect of disease screening, surgical strategy, indication of chemotherapy and molecular-targeted agents as well as monitoring tumor recurrence.